- Home
- KAVL vs NEUP Comparison
KAVL vs NEUP Comparison
Compare KAVL & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- NEUP
- Stock Information
- Founded
- KAVL 1998
- NEUP 1996
- Country
- KAVL United States
- NEUP United States
- Employees
- KAVL N/A
- NEUP 8
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- NEUP
- Sector
- KAVL Health Care
- NEUP
- Exchange
- KAVL Nasdaq
- NEUP Nasdaq
- Market Cap
- KAVL 9.6M
- NEUP 10.3M
- IPO Year
- KAVL N/A
- NEUP N/A
- Fundamental
- Price
- KAVL $0.51
- NEUP $4.22
- Analyst Decision
- KAVL
- NEUP Strong Buy
- Analyst Count
- KAVL 0
- NEUP 2
- Target Price
- KAVL N/A
- NEUP $28.00
- AVG Volume (30 Days)
- KAVL 214.4K
- NEUP 4.7M
- Earning Date
- KAVL 09-16-2025
- NEUP 11-21-2025
- Dividend Yield
- KAVL N/A
- NEUP N/A
- EPS Growth
- KAVL N/A
- NEUP N/A
- EPS
- KAVL N/A
- NEUP N/A
- Revenue
- KAVL $1,127,037.00
- NEUP $15,649,448.00
- Revenue This Year
- KAVL N/A
- NEUP N/A
- Revenue Next Year
- KAVL N/A
- NEUP N/A
- P/E Ratio
- KAVL N/A
- NEUP N/A
- Revenue Growth
- KAVL N/A
- NEUP N/A
- 52 Week Low
- KAVL $0.40
- NEUP $2.90
- 52 Week High
- KAVL $1.55
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- KAVL 39.13
- NEUP 32.72
- Support Level
- KAVL $0.53
- NEUP $4.53
- Resistance Level
- KAVL $0.61
- NEUP $8.44
- Average True Range (ATR)
- KAVL 0.04
- NEUP 0.95
- MACD
- KAVL -0.01
- NEUP -0.70
- Stochastic Oscillator
- KAVL 5.90
- NEUP 3.50
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating creative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About NEUP Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.